Groot et al. randomized 131 patients with HER2-negative Stage II/III breast cancer, without previously diagnosed diabetes and BMI ≥ 18 kg m2, to receive either a fasting mimicking diet (FMD) or their regular diet for 3 days prior to and during neoadjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.